Artificial intelligence and pathomics: prostate cancer
PA Moghadam, A Bashashati… - Urologic …, 2024 - urologic.theclinics.com
Since the introduction of the hematoxylin and eosin (H&E)-stained slide in 1876 as the
primary tool in the pathologist's toolbox up until the last decade, few tools, other than the …
primary tool in the pathologist's toolbox up until the last decade, few tools, other than the …
PSA velocity and doubling time in diagnosis and prognosis of prostate cancer
AJ Vickers, SF Brewster - British Journal of Medical and …, 2012 - journals.sagepub.com
Cancer is a growth process and it is natural that we should be concerned with how the
routinely used marker of prostate cancer tumour burden–PSA–changes over time. Such …
routinely used marker of prostate cancer tumour burden–PSA–changes over time. Such …
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Background Optimum management of clinically localised prostate cancer presents unique
challenges because of the highly variable and often indolent natural history of the disease …
challenges because of the highly variable and often indolent natural history of the disease …
Outcomes of localized prostate cancer following conservative management
Context Most newly diagnosed prostate cancers are clinically localized, and major treatment
options include surgery, radiation, or conservative management. Although conservative …
options include surgery, radiation, or conservative management. Although conservative …
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
Background: The natural history of prostate cancer is highly variable and difficult to predict
accurately. Better markers are needed to guide management and avoid unnecessary …
accurately. Better markers are needed to guide management and avoid unnecessary …
Molecular sampling of prostate cancer: a dilemma for predicting disease progression
Background Current prostate cancer prognostic models are based on pre-treatment prostate
specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are …
specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are …
PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume
EJ Whitman, J Groskopf, A Ali, Y Chen… - The Journal of …, 2008 - auajournals.org
Purpose: PCA3 is a prostate specific, nonprotein coding RNA that is over expressed in
prostate cancer. Recent studies showed the diagnostic potential of a urine based PCA3 for …
prostate cancer. Recent studies showed the diagnostic potential of a urine based PCA3 for …
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
Abstract Treatment decisions after diagnosis of clinically localised prostate cancer are
difficult due to variability in tumour behaviour. We therefore examined one of the most …
difficult due to variability in tumour behaviour. We therefore examined one of the most …
Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis
X Yin, Y Xiao, F Li, S Qi, Z Yin, J Gao - Medicine, 2016 - journals.lww.com
Inflammation is increasingly reported to be associated with the prognosis of patients with
cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with …
cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with …
Evaluating localized prostate cancer and identifying candidates for focal therapy
Can focal therapy successfully control prostate cancer? Also, if so, which patients should be
considered eligible? With limited data available from relatively few patients, these questions …
considered eligible? With limited data available from relatively few patients, these questions …